Dillon Patrick M, Brenin Christiana M, Slingluff Craig L
University of Virginia, Division of Hematology/Oncology, Charlottesville, VA 22908, USA.
University of Virginia, Department of Surgery, Charlottesville, VA 22908, USA.
Breast Cancer (Dove Med Press). 2020 Apr 3;12:69-75. doi: 10.2147/BCTT.S224758. eCollection 2020.
Vaccine therapies for treatment and prevention of cancer have seen modest degrees of efficacy with wide variation related to the tumor type, vaccine type, adjuvants and clinical setting for their study. Over the course of the last two decades, various peptide vaccines for breast cancer have been studied. The current leading peptide vaccine for human application is a HER2-based vaccine known as Nelipepimut-S, which has demonstrated immune activity and promising clinical activity in some settings. This review covers the development of this newer peptide vaccine for both HER2 amplified and non-amplified breast cancer.
用于治疗和预防癌症的疫苗疗法疗效一般，其疗效因肿瘤类型、疫苗类型、佐剂以及研究的临床环境不同而有很大差异。在过去二十年中，人们对多种用于乳腺癌的肽疫苗进行了研究。目前用于人体的领先肽疫苗是一种基于HER2的疫苗，名为Nelipepimut-S，它在某些情况下已显示出免疫活性和有前景的临床活性。这篇综述涵盖了这种新型肽疫苗针对HER2扩增和非扩增乳腺癌的研发情况。
